Osteoporosis: A disease in men

Clinical Orthopaedics and Related Research

Volumn 425, Issue , 2004, Pages 143-151

  Stock, Harlan ^a   Schneider, Adina ^a   Strauss, Elton ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANDROGEN RECEPTOR; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CYTOKINE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETIDRONIC ACID; FLUORIDE; INTERLEUKIN 1; INTERLEUKIN 6; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

BIOAVAILABILITY; BONE FRAGILITY; BONE MASS; BONE MATURATION; BONE MINERAL; CALCIUM INTAKE; CONFERENCE PAPER; DRUG BIOAVAILABILITY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; LIFE EXPECTANCY; MALE; METABOLIC BONE DISEASE; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

EID: 4043062275     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000136842.75487.e2     Document Type: Conference Paper

References (51)

1. Adami S, Prizzi R, Colapietro F: Alendronate for the treatment of osteoporosis in men. Calcif Tissue Int 69:239-241, 2001.
2. Amin S, Felson DT: Osteoporosis in men. Rheum Dis Clin North Am 27:19-47, 2001.
3. Bilezikian JP, Kurland ES: Therapy of male osteoporosis with parathyroid hormone. Calcif Tissue Int 69:248-251, 2001.
4. Bilezikian JP, Morishima A, Bell J, et al: Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339:599-603, 1998.
5. Cohen-Solal ME, Baudoin C, Omouri M, et al: Bone mass in middle aged osteoporotic men and their relatives: Familial effect. J Bone Miner Res 13:1909-1914, 1998.
6. Compston J: Secondary causes of osteoporosis in men. Calcif Tissue Int 69:193-195, 2001.
7. Consensus Development Conference V. 1993: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 90:646-650, 1994.
8. de Laet CE, van der Klift M, Hofman A, et al: Osteoporosis in men and women: A story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res 17:2231-2236, 2002.
9. Ettinger B, Black DM, Mitlak BH, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3 year randomized clinical trial. Multiple Outcomes of Raloxifene Investigation (MORE). JAMA 282:637-645, 1999.
10. Evans RA, Marel GM, Lancaster EK, et al: Bone mass is low in relatives of osteoporotic patients. Ann Intern Med 109:870-873, 1988.
11. Falahati-Nini A, Riggs BL, Atkinson EJ, et al: Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553-1560, 2000.
12. Farmer ME, White LR, Brody JA, Bailey KR: Race and sex differences in hip fracture incidence. Am J Public Health 74:1374-1380, 1984.
13. Finkelstein JS, Klibanski A, Neer RM, et al: Osteoporosis in men with idiopathic hypogonadotrophic hypogonadism. Ann Intern Med 106:354-361, 1987.
14. Francis RM: Androgen replacement in aging men. Calcif Tissue Int 69:235-238, 2001.
15. Gennari L, Becherini L, Falchetti A, et al: Genetics of osteoporosis: Role of steroid hormone receptor gene polymorphisms. J Steroid Biochem Mol Biol 81:1-24, 2002.
16. Gennari L, Brandi ML: Genetics of male osteoporosis. Calcif Tissue Int 69:200-204, 2001.
17. Gennari C, Seeman E: The First International Conference on Osteoporosis in Men, Siena, Italy, February 2001. 69:177-178, 2001.
18. Gillberg P, Mallmin H, Petren-Mallmin M, Ljunghall S, Nilsson AG: Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab 87:4900-4906, 2002.
19. Guo CY, Jones TH, Eastell R: Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. J Clin Endocrinol Metab 82:658-665, 1997.
20. Ismail AA, O'Neill TW, Cooper C, Silman AJ: Risk factors for vertebral deformities in men: relationship to number of vertebral deformities. J Bone Miner Res 15:278-283, 2000.
21. Ismail AA, Cooper C, Felsenberg D, et al: Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. Osteoporos Int 9:206-213, 1999.
22. Kanis J, Johnell O, Gullberg B, et al: Risk factors for hip fracture in men from Southern Europe: The MEDOS Study. Osteoporos Int 9:45-54, 1999.
23. Katznelson L, Finkelstein JS, Schoenfeld DA, et al: Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81:4358-4365, 1996.
24. Khosla S, Melton III LJ, Atkinson EJ, et al: Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266-2274, 1998.
25. Kurland ES, Rosen CJ, Cosman F, et al: Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 82:2799-2805, 1997.
26. Lindsay R, Cosman F: Osteoporosis. In Braunwald E, Fauci AS, Kasper DL, et al (eds). Harrison's Principles of Internal Medicine. Ed 15. New York, Mcgraw-Hill 2226-2237, 2001.
27. Lombardi A, Ross PD: The assessment of bone mass in men. Calcif Tissue Int 69:222-224, 2001.
28. Matthis C, Weber U, O'Neil TW, Raspe H: Health impact associated with vertebral deformities: Results from the European Vertebral Osteoporosis Study (EVOS). Osteoporos Int 8:364-372, 1998.
29. Neer RM, Arnaud CD, Zanchetta JR, et al: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441, 2001.
30. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN: Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 144:255-263, 1996.
31. O'Neill TW, Felsenberg D, Varlow J, et al: The prevalence of vertebral deformity in European men and women: The European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010-1018, 1996.
32. Pols HA, Felsenberg D, Hanley DA, et al: Multinational, placebo-controlled, randomized trial of the effect of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study: Fosamax International Trial Study Group. Osteoporos Int 9:461-468, 1999.
33. Orwoll E: Assessing bone density in men. J Bone Miner Res 15:1867-1870, 2000.
34. Orwoll E, Ettinger M, Weiss S, et al: Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610, 2000.
35. Orwoll ES, Scheele WH, Paul S, et al: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17, 2003.
36. Poor G, Atkinson EJ, O'Fallon WM, Melton III LJ: Predictors of hip fractures in elderly men. J Bone Miner Res 10:1900-1907, 1995.
37. Ralston SH: Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab 87:2460-2466, 2002.
38. Ringe JD, Rovati LC: Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 69:252-255, 2001.
39. Scane AC, Francis RM: Risk factors for osteoporosis in men. Clin Endocrinol 38:15-16, 1993.
40. Seeman E: The structural basis of bone fragility in men. Bone 25:143-147, 1999.
41. Seeman E: During aging, men lose less bone than woman. Calcif Tissue Int 69:205-208, 2001.
42. Siddiqui NA, Shetty KR: Osteoporosis in older men: Discovering when and how to treat it. Geriatrics 54:20-37, 1994.
43. Slemenda CW, Longcope C, Zhou L, et al: Sex steroids and bone mass in older men: Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 100:1755-1759, 1997.
44. Smith EP, Boyd J, Frank GR, et al: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056-1061, 1994.
45. Smith MR: Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 97:789-795, 2003.
46. Snyder PJ, Peachey H, Hannoush P, et al: Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966-1972, 1999.
47. Szulc P, Munoz F, Claustrat B, et al: Bioavailable estradiol may be an important determinant of osteoporosis in men: The MINOS study. J Clin Endocrinol Metab 86:192-199, 2001.
48. Trovas GP, Lyritis GP, Galanos A, Raptou P, Constanelou E: A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: Effects on bone mineral density and bone markers. J Bone Miner Res 17:521-527, 2002.
49. Walker-Bone K, Dennison E, Cooper C: Epidemiology of Osteoporosis. Rheum Dis Clin of North Am 27:1-18, 2001.
50. Zitzmann M, Brune M, Kornmann B, et al: The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin Endocrinol (Oxf) 55:649-657, 2001.
51. Zmuda MJ, Cauley JA, Kuller LH, et al: Androgen receptor CAG repeat length is associated with increased hip bone loss and vertebral fracture risk among older men. J Bone Miner Res 15:s491, (abstract M141) 2000.